Cancer Research and Treatment

Original Articles

Combination Treatment of Stereotactic Body Radiation Therapy and Immature Dendritic Cell Vaccination for Augmentation of Local and Systemic Effects: Chul Won Choi, Min Ho Jeong, You-Soo Park, Cheol-Hun Son, Hong-Rae Lee, Eun-Kyoung Koh; Cancer Res Treat. 2019;51(2):464-473. Published online June 6, 2018; DOI: https://doi.org/10.4143/crt.2018.186

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to investigate the efficacy of stereotactic body radiation therapy (SBRT) as a tumor-associated antigen (TAA) presentation method for dendritic cell (DC) sensitization and evaluate its effect in combination with immunotherapy using an intratumoral injection of immature DCs (iDCs).
Methods
and Materials CT-26 colon carcinoma cell was used as a cancer cell line. Annexin V staining and phagocytosis assays were performed to determine the appropriate radiation dose and incubation time to generate TAAs. BALB/c mice were used for in vivo experiments. Cancer cells were injected into the right legs and left flanks to generate primary and metastatic tumors, respectively. The mice were subjected to radiation therapy (RT) alone, intradermal injection of electroporated DCs alone, or RT in combination with iDC intratumoral injection (RT/iDC). Tumor growth measurement and survival rate analysis were performed. Enzyme-linked immunospot and cytotoxicity assays were performed to observe the effect of different treatments on the immune system.
Results
Annexin V staining and phagocytosis assays showed that 15 Gy radiation dose and 48 hours of incubation was appropriate for subsequent experiments. Maximum DC sensitization and T-cell stimulation was observed with RT as compared to other TAA preparation methods. In vivo assays revealed statistically significant delay in the growth of both primary and metastatic tumors in the RT/iDC group. The overall survival rate was the highest in the RT/iDC group.
Conclusion
The combination of SBRT and iDC vaccination may enhance treatment effects. Clinical trials and further studies are warranted in the future.

Citations

Citations to this article as recorded by

Neoadjuvant SBRT combined with immunotherapy in NSCLC: from mechanisms to therapy
Yanhong Shi, Xiaoyan Ma, Dan He, Bingwei Dong, Tianyun Qiao
Frontiers in Immunology.2023;[Epub] CrossRef
Therapeutic strategies for gastric cancer targeting immune cells: Future directions
Yan Zhao, Yuansong Bai, Meili Shen, Yapeng Li
Frontiers in Immunology.2022;[Epub] CrossRef
Recent Advances and Future Perspective of DC-Based Therapy in NSCLC
Iris A. E. van der Hoorn, Georgina Flórez-Grau, Michel M. van den Heuvel, I. Jolanda M. de Vries, Berber Piet
Frontiers in Immunology.2021;[Epub] CrossRef
Successful Treatment of Advanced Gastric Cancer with Brain Metastases through an Abscopal Effect by Radiation and Immune Checkpoint Inhibitor Therapy
Momotaro Muto, Hirotaka Nakata, Kenichi Ishigaki, Shion Tachibana, Moe Yoshida, Mizue Muto, Nobuyuki Yanagawa, Toshikatsu Okumura
Journal of Gastric Cancer.2021; 21(3): 319. CrossRef
Intelligent photothermal dendritic cells restart the cancer immunity cycle through enhanced immunogenic cell death
Zhihong Sun, Guanjun Deng, Xinghua Peng, Xiuli Xu, Lanlan Liu, Jiaofeng Peng, Yifan Ma, Pengfei Zhang, Austin Wen, Yifan Wang, Zhaogang Yang, Ping Gong, Wen Jiang, Lintao Cai
Biomaterials.2021; 279: 121228. CrossRef
Prediction and identification of novel HLA-A*0201-restricted cytotoxic T lymphocyte epitopes from endocan
Gaohai Shao, Qingjun Liu, Ling Yang, Guibo Feng, Wang Zhao, Zhongyan Huang, Zhao Yang
Journal of Inflammation.2020;[Epub] CrossRef
HMGB1 in Radiotherapy: A Two Headed Signal Regulating Tumor Radiosensitivity and Immunity

Yin Liao, Shuya Liu, Shaozhi Fu, Jingbo Wu
OncoTargets and Therapy.2020; Volume 13: 6859. CrossRef
Immunotherapy as sensitizer for local radiotherapy
Ben G.L. Vanneste, Evert J Van Limbergen, Ludwig Dubois, Iryna V. Samarska, L. Wieten, M. J.B. Aarts, T. Marcelissen, Dirk De Ruysscher
OncoImmunology.2020;[Epub] CrossRef
Effective Combinations of Radiotherapy and Immunotherapy in the Treatment of Esophageal Squamous Cell Carcinoma
Yang Yang, Hong Ge
Future Oncology.2020; 16(31): 2537. CrossRef
Abscopal effect of stereotactic radiotherapy combined with anti‐PD‐1/PD‐L1 immunotherapy: Mechanisms, clinical efficacy, and issues
Hongqing Zhuang
Cancer Communications.2020; 40(12): 649. CrossRef
A Characterization of Dendritic Cells and Their Role in Immunotherapy in Glioblastoma: From Preclinical Studies to Clinical Trials
Siddhartha Srivastava, Christina Jackson, Timothy Kim, John Choi, Michael Lim
Cancers.2019; 11(4): 537. CrossRef
Current status of immune checkpoint inhibition in early-stage NSCLC
J. Vansteenkiste, E. Wauters, B. Reymen, C.J. Ackermann, S. Peters, D. De Ruysscher
Annals of Oncology.2019; 30(8): 1244. CrossRef
Local Irradiation Sensitized Tumors to Adoptive T Cell Therapy via Enhancing the Cross-Priming, Homing, and Cytotoxicity of Antigen-Specific CD8 T Cells
Jin-Zhi Lai, Yan-Yang Zhu, Mei Ruan, Ling Chen, Qiu-Yu Zhang
Frontiers in Immunology.2019;[Epub] CrossRef
Nutraceutical Compounds as Sensitizers for Cancer Treatment in Radiation Therapy
Marco Calvaruso, Gaia Pucci, Rosa Musso, Valentina Bravatà, Francesco P. Cammarata, Giorgio Russo, Giusi I. Forte, Luigi Minafra
International Journal of Molecular Sciences.2019; 20(21): 5267. CrossRef

8,800 View
262 Download
16 Web of Science
14 Crossref

Survey of the Patterns of Using Stereotactic Ablative Radiotherapy for Early-Stage Non-small Cell Lung Cancer in Korea: Sanghyuk Song, Ji Hyun Chang, Hak Jae Kim, Yeon Sil Kim, Jin Hee Kim, Yong Chan Ahn, Jae-Sung Kim, Si Yeol Song, Sung Ho Moon, Moon June Cho, Seon Min Youn; Cancer Res Treat. 2017;49(3):688-694. Published online October 31, 2016; DOI: https://doi.org/10.4143/crt.2016.219

Abstract PDF Supplementary Material PubReader ePub

Purpose
Stereotactic ablative radiotherapy (SABR) is an effective emerging technique for early-stage non-small cell lung cancer (NSCLC). We investigated the current practice of SABR for early-stage NSCLC in Korea.
Materials and Methods
We conducted a nationwide survey of SABR for NSCLC by sending e-mails to all board-certified members of the Korean Society for Radiation Oncology. The survey included 23 questions focusing on the technical aspects of SABR and 18 questions seeking the participants’ opinions on specific clinical scenarios in the use of SABR for early-stage NSCLC. Overall, 79 radiation oncologists at 61/85 specialist hospitals in Korea (71.8%) responded to the survey.
Results
SABR was used at 33 institutions (54%) to treat NSCLC. Regarding technical aspects, the most common planning methods were the rotational intensity-modulated technique (59%) and the static intensity-modulated technique (49%). Respiratory motion was managed by gating (54%) or abdominal compression (51%), and 86% of the planning scans were obtained using 4-dimensional computed tomography. In the clinical scenarios, the most commonly chosen fractionation schedule for peripherally located T1 NSCLC was 60 Gy in four fractions. For centrally located tumors and T2 NSCLC, the oncologists tended to avoid SABR for radiotherapy, and extended the fractionation schedule.
Conclusion
The results of our survey indicated that SABR is increasingly being used to treat NSCLC in Korea. However, there were wide variations in the technical protocols and fractionation schedules of SABR for early-stage NSCLC among institutions. Standardization of SABR is necessary before implementing nationwide, multicenter, randomized studies.

Citations

Citations to this article as recorded by

Guidelines for safe practice of stereotactic body (ablative) radiation therapy: RANZCR 2023 update
Howard Yu‐hao Liu, Nicholas Hardcastle, Michael Bailey, Shankar Siva, Anna Seeley, Tamara Barry, Jeremy Booth, Louis Lao, Michelle Roach, Stacey Buxton, David Thwaites, Matthew Foote
Journal of Medical Imaging and Radiation Oncology.2024; 68(2): 217. CrossRef
Technical Giants But Biologic Infants: Defining a More Sophisticated Role for Local Therapy in Metastatic Disease
Sophia C. Kamran, David Palma, Matthew S. Katz, Anthony L. Zietman
Seminars in Radiation Oncology.2021; 31(3): 200. CrossRef
MiR-223-3p regulates cell viability, migration, invasion, and apoptosis of non-small cell lung cancer cells by targeting RHOB
Shufang Li, Yuping Feng, Yuxia Huang, Yu Liu, Yanxi Wang, Yan Liang, Hui Zeng, Hong Qu, Ling Wei
Open Life Sciences.2020; 15(1): 389. CrossRef

9,830 View
235 Download
3 Web of Science
3 Crossref

Minimally Invasive Stereotactical Radio-ablation of Adrenal Metastases as an Alternative to Surgery: Ciro Franzese, Davide Franceschini, Luca Cozzi, Giuseppe D’Agostino, Tiziana Comito, Fiorenza De Rose, Pierina Navarria, Pietro Mancosu, Stefano Tomatis, Antonella Fogliata, Marta Scorsetti; Cancer Res Treat. 2017;49(1):20-28. Published online April 27, 2016; DOI: https://doi.org/10.4143/crt.2016.057

Abstract PDF PubReader ePub

Purpose
The purpose of this study was to study the clinical outcome for patients with metastases of the adrenal gland treated with stereotactic body radiation therapy.
Materials and Methods
Forty-six patients were studied retrospectively. The dose prescription was 40 Gy in four fractions. Dosimetric analysis was performed using the dose volume histograms while clinical outcome was assessed using actuarial analysis with determination of the overall survival (OS) and local control (LC) rates.
Results
The planning objectives were met for all patients. With a median follow-up period of 7.6 months, at the last follow-up 42 patients (91.3%) were alive and four had died because of distant progression. The actuarial mean OS was 28.5±1.6 months, the median was not reached. One-year and 2-year OS were 87.6±6.1%. None of the risk factors was significant in univariate analysis. Actuarial mean LC was 14.6±1.8 months (95% confidence interval [CI], 11.0 to 18.2) and median LC was 14.5±2.0 months (95% CI, 10.5 to 18.5). One-year and 2-year LC were 65.5±11.9% and 40.7±15.8%, respectively. A mild profile of toxicity was observed in the cohort of patients. Forty patients (86.9%) showed no complication (grade 0); two patients reported asthenia, six patients (13.1%) reported either pain, nausea, or vomiting. Of these six patients, five patients (10.9%) were scored as grade 1 toxicity while one patient (2.2%) was scored as grade 2.
Conclusion
Stereotactic body radiation therapy treatment provided an adequate clinical response in the management of adrenal gland metastases.

Citations

Citations to this article as recorded by

Two-institution results of Stereotactic Body Radiation Therapy (SBRT) for treating adrenal gland metastases from liver cancer
Bichun Xu, Xianzhi Zhao, Di Chen, Wenjuan Zhao, Xiaoyan Wang, Changhua Ding, Zhiyong Yuan, Huojun Zhang
BMC Cancer.2023;[Epub] CrossRef
Radiation Therapy in the Management of Adrenal Metastases
Ciro Franzese, Sara Stefanini, Marta Scorsetti
Seminars in Radiation Oncology.2023; 33(2): 193. CrossRef
The efficacy and outcomes of stereotactic body radiotherapy in adrenal gland metastases
Esra Kekilli, Taciser Demirkasımoğlu
Journal of Cancer Research and Therapeutics.2023; 19(Suppl 1): S47. CrossRef
Twenty Years of Advancements in a Radiotherapy Facility: Clinical Protocols, Technology, and Management
Stefano Tomatis, Pietro Mancosu, Giacomo Reggiori, Francesca Lobefalo, Pasqualina Gallo, Nicola Lambri, Lucia Paganini, Francesco La Fauci, Andrea Bresolin, Sara Parabicoli, Marco Pelizzoli, Pierina Navarria, Ciro Franzese, Domenico Lenoci, Marta Scorsett
Current Oncology.2023; 30(7): 7031. CrossRef
Risk factors of local control in adrenal metastases treated by stereotactic body radiation therapy - a systematic review and meta-analysis
Xuehong Liao, Kazushi Kishi, Kaixin Du, Ritsuko Komaki, Junetsu Mizoe, Gosuke Aikawa, Wei Zheng, Chao Pan
Frontiers in Oncology.2023;[Epub] CrossRef
Management of an Unusual Metastasis of Cervical Cancer in the Adrenal Bed With Stereotactic Ablative Body Radiation Therapy
Raul Puente-Vallejo, Pamela Ochoa, Cristina Núñez, Luis De Los Reyes
Cureus.2022;[Epub] CrossRef
Stereotactic body radiotherapy of adrenal metastases—A dose‐finding study
Daniel Buergy, Florian Würschmidt, Eleni Gkika, Juliane Hörner‐Rieber, Stefan Knippen, Sabine Gerum, Panagiotis Balermpas, Christoph Henkenberens, Theresa Voglhuber, Christine Kornhuber, Steffen Barczyk, Barbara Röper, Ali Rashid, Oliver Blanck, Andrea Wi
International Journal of Cancer.2022; 151(3): 412. CrossRef
Stereotactic MR-Guided Radiotherapy for Adrenal Gland Metastases: First Clinical Results
Morgan Michalet, Ons Bettaïeb, Samia Khalfi, Asma Ghorbel, Simon Valdenaire, Pierre Debuire, Norbert Aillères, Roxana Draghici, Mailys De Méric De Bellefon, Marie Charissoux, Pierre Boisselier, Sylvain Demontoy, Alexis Marguerit, Morgane Cabaillé, Marie C
Journal of Clinical Medicine.2022; 12(1): 291. CrossRef
Stereotactic or conformal radiotherapy for adrenal metastases: Patient characteristics and outcomes in a multicenter analysis
Daniel Buergy, Florian Würschmidt, Eleni Gkika, Juliane Hörner‐Rieber, Stefan Knippen, Sabine Gerum, Panagiotis Balermpas, Christoph Henkenberens, Theresa Voglhuber, Christine Kornhuber, Steffen Barczyk, Barbara Röper, Ali Rashid, Oliver Blanck, Andrea Wi
International Journal of Cancer.2021; 149(2): 358. CrossRef
Modeling of Tumor Control Probability in Stereotactic Body Radiation Therapy for Adrenal Tumors
Priscilla K. Stumpf, Ellen D. Yorke, Issam El Naqa, Kyle C. Cuneo, Jimm Grimm, Karyn A. Goodman
International Journal of Radiation Oncology*Biology*Physics.2021; 110(1): 217. CrossRef
Phase II trial of stereotactic body radiation therapy on adrenal gland metastases: evaluation of efficacy and impact on hormonal production
Ciro Franzese, Sara Stefanini, Maria Massaro, Tiziana Comito, Pierina Navarria, Elena Clerici, Ausilia Teriaca, Davide Franceschini, Giacomo Reggiori, Stefano Tomatis, Andrea Lania, Marta Scorsetti
Journal of Cancer Research and Clinical Oncology.2021; 147(12): 3619. CrossRef
Stereotactic body radiation therapy for adrenal gland metastases: outcome and predictive factors from a multicenter analysis
Ciro Franzese, Luca Nicosia, Giuseppe Facondo, Lorenzo Lo Faro, Francesco Cuccia, Gianluca Vullo, Mattia Falchetto Osti, Filippo Alongi, Marta Scorsetti
Clinical & Experimental Metastasis.2021; 38(6): 511. CrossRef
Stereotactic Body Radiation Therapy of Adrenal Metastases: A Pooled Meta-Analysis and Systematic Review of 39 Studies with 1006 Patients
William C. Chen, Joe D. Baal, Ulysis Baal, Jonathan Pai, Alexander Gottschalk, Lauren Boreta, Steve E. Braunstein, David R. Raleigh
International Journal of Radiation Oncology*Biology*Physics.2020; 107(1): 48. CrossRef
Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients
Laila König, Matthias F. Häfner, Sonja Katayama, Stefan A. Koerber, Eric Tonndorf-Martini, Denise Bernhardt, Bastian von Nettelbladt, Fabian Weykamp, Philipp Hoegen, Sebastian Klüter, Matthew S. Susko, Jürgen Debus, Juliane Hörner-Rieber
Radiation Oncology.2020;[Epub] CrossRef
Clinical efficacy of Stereotactic Body Radiation Therapy (SBRT) for adrenal gland metastases: A multi-center retrospective study from China
Xianzhi Zhao, Xiaofei Zhu, Hongqing Zhuang, Xueling Guo, Yongchun Song, Xiaoping Ju, Ping Wang, Zhiyong Yuan, Huojun Zhang
Scientific Reports.2020;[Epub] CrossRef
Single-institutional outcome-analysis of low-dose stereotactic body radiation therapy (SBRT) of adrenal gland metastases
Theresa Voglhuber, Kerstin A. Kessel, Markus Oechsner, Marco M. E. Vogel, Jürgen E. Gschwend, Stephanie E. Combs
BMC Cancer.2020;[Epub] CrossRef
Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity
Ciro Franzese, Marco Lorenzo Bonu, Tiziana Comito, Elena Clerici, Mauro Loi, Pierina Navarria, Davide Franceschini, Tiziana Pressiani, Lorenza Rimassa, Marta Scorsetti
Journal of Cancer Research and Clinical Oncology.2020; 146(9): 2289. CrossRef
Assessing the role of Stereotactic Body Radiation Therapy in a large cohort of patients with lymph node oligometastases: Does it affect systemic treatment’s intensification?
Ciro Franzese, Marco Badalamenti, Tiziana Comito, Davide Franceschini, Elena Clerici, Pierina Navarria, Mauro Loi, Giuseppe D'agostino, Davide Baldaccini, Ilaria Chiola, Giacomo Reggiori, Pietro Mancosu, Stefano Tomatis, Marta Scorsetti
Radiotherapy and Oncology.2020; 150: 184. CrossRef
Adrenal SBRT: a multi-institutional review of treatment outcomes and toxicity
Corbin A. Helis, Ryan T. Hughes, Karina Nieto, Adannia Ufondu, Emily C. Daugherty, Michael K. Farris
Clinical & Experimental Metastasis.2020; 37(5): 585. CrossRef
Stereotactic body radiotherapy for adrenal oligometastasis in lung cancer patients
Fabio Arcidiacono, Cynthia Aristei, Alessandro Marchionni, Marco Italiani, Cristian Paolo Luca Fulcheri, Simonetta Saldi, Michelina Casale, Gianluca Ingrosso, Paola Anselmo, Ernesto Maranzano
The British Journal of Radiology.2020; 93(1115): 20200645. CrossRef
Hypofractionated Radiotherapy for 35 Patients with Adrenal Metastases: A Single-Institution Experience

Ruizhi Zhao, Yuchao Ma, Siran Yang, Qingfeng Liu, Yuan Tang, Kai Wang, Ye Zhang, Nan Bi, Hongmei Zhang, Junlin Yi, Yexiong Li, Jingwei Luo, Jianping Xiao
Cancer Management and Research.2020; Volume 12: 11563. CrossRef
Usefulness of Stereotactic Body Radiation Therapy for Treatment of Adrenal Gland Metastases
Cyrielle Scouarnec, David Pasquier, Joel Luu, Florence le Tinier, Loïc Lebellec, Erwann Rault, Eric Lartigau, Xavier Mirabel
Frontiers in Oncology.2019;[Epub] CrossRef
Stereotactic body radiation therapy for adrenal gland metastases: Outcomes and toxicity
Diego A.S. Toesca, Amanda J. Koong, Rie von Eyben, Albert C. Koong, Daniel T. Chang
Advances in Radiation Oncology.2018; 3(4): 621. CrossRef
Role of Daily Plan Adaptation in MR-Guided Stereotactic Ablative Radiation Therapy for Adrenal Metastases
Miguel A. Palacios, Omar Bohoudi, Anna M.E. Bruynzeel, John R. van Sörsen de Koste, Paul Cobussen, Ben J. Slotman, Frank J. Lagerwaard, Suresh Senan
International Journal of Radiation Oncology*Biology*Physics.2018; 102(2): 426. CrossRef
Short-term outcomes and clinical efficacy of stereotactic body radiation therapy (SBRT) in treatment of adrenal gland metastases from lung cancer
Xianzhi Zhao, Xiaofei Zhu, Jianfeng Fei, Haipeng Ren, Yangsen Cao, Xiaoping Ju, Zhiyong Yuan, Huojun Zhang
Radiation Oncology.2018;[Epub] CrossRef
Real-Time Tumor-Tracking Radiotherapy and General Stereotactic Body Radiotherapy for Adrenal Metastasis in Patients With Oligometastasis
Norio Katoh, Hiroshi Onishi, Yusuke Uchinami, Tetsuya Inoue, Kengo Kuriyama, Kentaro Nishioka, Shinichi Shimizu, Takafumi Komiyama, Naoki Miyamoto, Hiroki Shirato
Technology in Cancer Research & Treatment.2018;[Epub] CrossRef
Adrenal insufficiency in Bilateral Adrenal Metastasis implemented SBRT
Cihan YB
Journal of Radiology and Oncology.2018; : 009. CrossRef
Stereotactic/hypofractionated body radiation therapy as an effective treatment for lymph node metastases from colorectal cancer: an institutional retrospective analysis
Ciro Franzese, Antonella Fogliata, Tiziana Comito, Angelo Tozzi, Cristina Iftode, Elena Clerici, Davide Franceschini, Pierina Navarria, Anna Maria Ascolese, Lucia Di Brina, Fiorenza De Rose, Giuseppe R D'Agostino, Luca Cozzi, Marta Scorsetti
The British Journal of Radiology.2017;[Epub] CrossRef
SBRT to adrenal metastases provides high local control with minimal toxicity
Kristin Plichta, Nathan Camden, Muhammed Furqan, Taher Abu Hejleh, Gerald H. Clamon, Jun Zhang, Ryan T. Flynn, Sudershan K. Bhatia, Mark C. Smith, John M. Buatti, Bryan G. Allen
Advances in Radiation Oncology.2017; 2(4): 581. CrossRef

10,256 View
201 Download
35 Web of Science
29 Crossref

Review Article

The Role of Stereotactic Ablative Radiotherapy for Early-Stage and Oligometastatic Non-small Cell Lung Cancer: Evidence for Changing Paradigms: Max Dahele, Suresh Senan; Cancer Res Treat. 2011;43(2):75-82. Published online June 30, 2011; DOI: https://doi.org/10.4143/crt.2011.43.2.75

Abstract PDF PubReader ePub

A compelling body of non-randomized evidence has established stereotactic ablative lung radiotherapy (SABR) as a standard of care for medically inoperable patients with peripheral early-stage non-small cell lung cancer (NSCLC). This convenient outpatient therapy, which is typically delivered in 3-8 fractions, is also well tolerated by elderly and frail patients, makes efficient use of resources and is feasible using standard commercial equipment. The introduction of lung SABR into large populations has led to an increased utilization of radiotherapy, a reduction in the proportion of untreated patients and an increase in overall survival. In selected patients, the same ablative technology can now achieve durable local control of NSCLC metastases in a variety of common locations including the adrenal glands, bone, brain, and liver. At the same time as this, advances in prognostic molecular markers and targeted systemic therapies mean that there is now a subgroup of patients with stage IV NSCLC and a median survival of around 2 years. This creates opportunities for new trials that incorporate SABR and patient-specific systemic strategies. This selective mini-review focuses on the emerging role of SABR in patients with early-stage and oligometastatic NSCLC.

Citations

Citations to this article as recorded by

Navigating patient journey in early diagnosis of lung cancer in India
Bivas Biswas, Deepak Talwar, Priti Meshram, Pramod K. Julka, Anurag Mehta, SP Somashekhar, Srinivas Chilukuri, Abhishek Bansal
Lung India.2023; 40(1): 48. CrossRef
Design, Synthesis and Anticancer Evaluation of Nitroimidazole Radiosensitisers
Lydia P. Liew, Avik Shome, Way W. Wong, Cho R. Hong, Kevin O. Hicks, Stephen M. F. Jamieson, Michael P. Hay
Molecules.2023; 28(11): 4457. CrossRef
Breast Metastasis of Lung Cancer After Computed Tomography-Guided Core Needle Biopsy: A Case Report
Rong Zhao, Jun Xing, Jinnan Gao
Frontiers in Surgery.2022;[Epub] CrossRef
Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with “curative” intent
Michela Buglione, Barbara Alicja Jereczek-Fossa, Marco Lorenzo Bonù, Davide Franceschini, Andrei Fodor, Isa Bossi Zanetti, Marianna Alessandra Gerardi, Paolo Borghetti, Davide Tomasini, Nadia Gisella Di Muzio, Olga Oneta, Marta Scorsetti, Ciro Franzese, P
Lung Cancer.2020; 141: 1. CrossRef
Staging Lung Cancer
Girish S. Shroff, Chitra Viswanathan, Brett W. Carter, Marcelo F. Benveniste, Mylene T. Truong, Bradley S. Sabloff
Radiologic Clinics of North America.2018; 56(3): 411. CrossRef
Stereotactic Body Radiation Therapy for Early-Stage Non–Small Cell Lung Cancer: A Primer for Radiologists
Jennifer A. Febbo, Ramya S. Gaddikeri, Palmi N. Shah
RadioGraphics.2018; 38(5): 1312. CrossRef
Preliminary comparison of the registration effect of 4D-CBCT and 3D-CBCT in image-guided radiotherapy of Stage IA non–small-cell lung cancer
Zhibo Tan, Chuanyao Liu, Ying Zhou, Weixi Shen
Journal of Radiation Research.2017; 58(6): 854. CrossRef
Narcissus, the Beam, and lung cancer
Gaetano Rocco
The Journal of Thoracic and Cardiovascular Surgery.2016; 152(2): 338. CrossRef
Efficacy of stereotactic radiotherapy for brain metastases using dynamic jaws technology in the helical tomotherapy system
Taro Murai, Akihiro Hayashi, Yoshihiko Manabe, Chikao Sugie, Taiki Takaoka, Takeshi Yanagi, Tetsuya Oguri, Masayuki Matsuo, Yoshimasa Mori, Yuta Shibamoto
The British Journal of Radiology.2016; 89(1066): 20160374. CrossRef
Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium
Erik O. Pettersen, Peter Ebbesen, Roben G. Gieling, Kaye J. Williams, Ludwig Dubois, Philippe Lambin, Carol Ward, James Meehan, Ian H. Kunkler, Simon P. Langdon, Anne H. Ree, Kjersti Flatmark, Heidi Lyng, Maria J. Calzada, Luis del Peso, Manuel O. Landazu
Journal of Enzyme Inhibition and Medicinal Chemistry.2015; 30(5): 689. CrossRef
Monte Carlo validation of the TrueBeam 10XFFF phase–space files for applications in lung SABR
Tony Teke, Cheryl Duzenli, Alanah Bergman, Francis Viel, Parmveer Atwal, Ermias Gete
Medical Physics.2015; 42(12): 6863. CrossRef
Stratégies d’évaluation de la réponse après irradiation stéréotaxique des cancers bronchiques primitifs et des métastases pulmonaires
I. Barillot, O. Munier, M. Hatime, F. Mornex
Cancer/Radiothérapie.2014; 18(4): 308. CrossRef
Short-Course Treatment With Gefitinib Enhances Curative Potential of Radiation Therapy in a Mouse Model of Human Non-Small Cell Lung Cancer
Sivan M. Bokobza, Yanyan Jiang, Anika M. Weber, Aoife M. Devery, Anderson J. Ryan
International Journal of Radiation Oncology*Biology*Physics.2014; 88(4): 947. CrossRef
Can an alternative backround-corrected [18F] fluorodeoxyglucose (FDG) standard uptake value (SUV) be used for monitoring tumor local control following lung cancer stereotactic body radiosurgery?
Charles Shang, Michael Kasper, Vindu Kathriarachchi, Rashmi Benda, Joseph Kleinman, Jeremy Cole, Timothy Williams
International Journal of Cancer Therapy and Oncology.2014; 2(3): 020317. CrossRef
Stereotactic ablative body radiotherapy combined with immunotherapy: Present status and future perspectives
N.H. Rekers, E.G.C. Troost, C.M.L. Zegers, W.T.V. Germeraad, L.J. Dubois, P. Lambin
Cancer/Radiothérapie.2014; 18(5-6): 391. CrossRef
Cáncer de pulmón
P. Resano Barrio, Y. Anta Mejía
Medicine - Programa de Formación Médica Continuada Acreditado.2014; 11(67): 3983. CrossRef
Increasing Use of Advanced Radiation Therapy Technologies in the Last 30 Days of Life Among Patients Dying As a Result of Cancer in the United States
B. Ashleigh Guadagnolo, Kai-Ping Liao, Sharon H. Giordano, Linda S. Elting, Thomas A. Buchholz, Ya-Chen Tina Shih
Journal of Oncology Practice.2014; 10(4): e269. CrossRef
Extra-thoracic tumor burden but not thoracic tumor burden on 18F-FDG PET/CT is an independent prognostic biomarker for extensive-disease small cell lung cancer
Jong-Ryool Oh, Ji-Hyoung Seo, Chae Moon Hong, Shin Young Jeong, Sang-Woo Lee, Jaetae Lee, Jung-Joon Min, Ho-Chun Song, Hee-Seung Bom, Young-Chul Kim, Byeong-Cheol Ahn
Lung Cancer.2013; 81(2): 218. CrossRef
Changing trends in radiation therapy technologies in the last year of life for patients diagnosed with metastatic cancer in the United States
B. Ashleigh Guadagnolo, Jinhai Huo, Kai‐Ping Liao, Thomas A. Buchholz, Prajnan Das
Cancer.2013; 119(5): 1089. CrossRef
Escaping death to quiescence: Avoiding mitotic catastrophe after DNA damage
Zhiyuan Shen, Steven C. Huhn, Bruce G. Haffty
Cell Cycle.2013; 12(11): 1664. CrossRef
CyberKnife robotic image-guided stereotactic radiotherapy for oligometastic cancer
B.A. Jereczek-Fossa, I. Bossi-Zanetti, R. Mauro, G. Beltramo, L. Fariselli, L.C. Bianchi, C. Fodor, P. Fossati, G. Baroni, R. Orecchia
Strahlentherapie und Onkologie.2013; 189(6): 448. CrossRef
The development of stereotactic body radiotherapy (SBRT) for medically inoperable early stage non-small cell lung cancer: an international phenomenon
Gregory M. M. Videtic
Journal of Radiation Oncology.2012; 1(1): 3. CrossRef
Improving lung cancer survival; time to move on
Marlies E Heuvers, Joost P Hegmans, Bruno H Stricker, Joachim G Aerts
BMC Pulmonary Medicine.2012;[Epub] CrossRef
Radiographic changes after lung stereotactic ablative radiotherapy (SABR) – Can we distinguish recurrence from fibrosis? A systematic review of the literature
Kitty Huang, Max Dahele, Suresh Senan, Matthias Guckenberger, George B. Rodrigues, Aaron Ward, R. Gabriel Boldt, David A. Palma
Radiotherapy and Oncology.2012; 102(3): 335. CrossRef

12,977 View
103 Download
24 Crossref

First
Prev
Page of 1
Next
Last

Search